Do analysts recommend LIAN or ARTL?

Artelo Biosciences has a consensus target price of $54.00, suggesting a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable earnings & valuation, LIAN or ARTL?

LianBio is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A

Is LIAN or ARTL more profitable?

LianBio's return on equity of -33.17% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Artelo Biosciences N/A -1,600.12% -224.62%

Is ARTL or BFRG more profitable?

Bullfrog AI's return on equity of -217.80% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Bullfrog AI N/A -217.80% -174.57%

Do analysts prefer LNAI or ARTL?

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better valuation & earnings, LNAI or ARTL?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A

Is LNAI or ARTL more profitable?

Lunai Bioworks' return on equity of -1,243.45% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Artelo Biosciences N/A -1,600.12% -224.62%

Do analysts recommend ARTL or FNCH?

Artelo Biosciences currently has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ARTL or FNCH?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is ARTL or FNCH more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Finch Therapeutics Group N/A -69.14% -26.92%

Which has better valuation and earnings, ARTL or CMMB?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Is ARTL or CMMB more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Chemomab Therapeutics N/A -89.03% -79.68%

Artelo Biosciences (ARTL) Competitors

$1.16 -0.10 (-7.94%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$1.19 +0.03 (+2.24%)

As of 06/24/2026 07:50 PM Eastern

Compare

ARTL vs. LIAN, BFRG, LNAI, FNCH, and CMMB

Should you buy Artelo Biosciences stock or one of its competitors? MarketBeat compares Artelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artelo Biosciences include LianBio (LIAN), Bullfrog AI (BFRG), Lunai Bioworks (LNAI), Finch Therapeutics Group (FNCH), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

How does Artelo Biosciences compare to LianBio?

LianBio (NASDAQ:LIAN) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Artelo Biosciences has a consensus target price of $54.00, suggesting a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

LianBio is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

In the previous week, LianBio's average media sentiment score of 0.00 equaled Artelo Biosciences'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Artelo Biosciences	Neutral

LianBio's return on equity of -33.17% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market.

74.8% of LianBio shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

LianBio beats Artelo Biosciences on 6 of the 10 factors compared between the two stocks.

How does Artelo Biosciences compare to Bullfrog AI?

Artelo Biosciences (NASDAQ:ARTL) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 14.7% of Bullfrog AI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bullfrog AI has higher revenue and earnings than Artelo Biosciences. Bullfrog AI is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Bullfrog AI	$120K	99.50	-$6.50M	-$0.54	N/A

Artelo Biosciences currently has a consensus target price of $54.00, suggesting a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Artelo Biosciences is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Artelo Biosciences has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.89, suggesting that its share price is 389% less volatile than the broader market.

In the previous week, Bullfrog AI had 1 more articles in the media than Artelo Biosciences. MarketBeat recorded 1 mentions for Bullfrog AI and 0 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.00 equaled Bullfrog AI'saverage media sentiment score.

Company	Overall Sentiment
Artelo Biosciences	Neutral
Bullfrog AI	Neutral

Bullfrog AI's return on equity of -217.80% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Bullfrog AI	N/A	-217.80%	-174.57%

Summary

Bullfrog AI beats Artelo Biosciences on 8 of the 12 factors compared between the two stocks.

How does Artelo Biosciences compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Lunai Bioworks' average media sentiment score of 0.12 beat Artelo Biosciences' score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Artelo Biosciences	Neutral

Lunai Bioworks has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

Lunai Bioworks' return on equity of -1,243.45% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Artelo Biosciences beats Lunai Bioworks on 6 of the 11 factors compared between the two stocks.

How does Artelo Biosciences compare to Finch Therapeutics Group?

Artelo Biosciences (NASDAQ:ARTL) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Finch Therapeutics Group's return on equity of -69.14% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Artelo Biosciences currently has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Artelo Biosciences has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

In the previous week, Artelo Biosciences' average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company	Overall Sentiment
Artelo Biosciences	Neutral
Finch Therapeutics Group	Neutral

Summary

Finch Therapeutics Group beats Artelo Biosciences on 6 of the 10 factors compared between the two stocks.

How does Artelo Biosciences compare to Chemomab Therapeutics?

Artelo Biosciences (NASDAQ:ARTL) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Artelo Biosciences' average media sentiment score of 0.00 equaled Chemomab Therapeutics'average media sentiment score.

Company	Overall Sentiment
Artelo Biosciences	Neutral
Chemomab Therapeutics	Neutral

Artelo Biosciences presently has a consensus price target of $54.00, indicating a potential upside of 4,555.17%. Chemomab Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,512.90%. Given Artelo Biosciences' higher probable upside, equities analysts plainly believe Artelo Biosciences is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Artelo Biosciences has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Chemomab Therapeutics' return on equity of -89.03% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Summary

Chemomab Therapeutics beats Artelo Biosciences on 9 of the 11 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTL vs. The Competition

Export

Metric	Artelo Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.94M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.04	20.50	25.37	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-0.61	8.26	10.76	6.41
Net Income	-$12.88M	$23.91M	$3.56B	$337.14M
7 Day Performance	-7.94%	2.12%	0.99%	-1.06%
1 Month Performance	-2.52%	2.40%	0.79%	0.49%
1 Year Performance	-93.74%	57.09%	30.25%	28.43%

Artelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTL Artelo Biosciences	1.2173 of 5 stars	$1.16 -7.9%	$54.00 +4,555.2%	-93.4%	$2.94M	N/A	N/A	5
LIAN LianBio	N/A	$0.11 -30.8%	N/A	-73.0%	$11.95M	N/A	N/A	110	Gap Down
BFRG Bullfrog AI	0.6416 of 5 stars	$0.69 +8.6%	N/A	-59.8%	$11.84M	$116.67K	N/A	4	News Coverage Gap Up
LNAI Lunai Bioworks	0.5068 of 5 stars	$2.85 +9.2%	N/A	N/A	$11.83M	N/A	N/A	20	High Trading Volume
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTL) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artelo Biosciences (ARTL) Competitors

ARTL vs. LIAN, BFRG, LNAI, FNCH, and CMMB

How does Artelo Biosciences compare to LianBio?

Summary

How does Artelo Biosciences compare to Bullfrog AI?

Summary

How does Artelo Biosciences compare to Lunai Bioworks?

Summary

How does Artelo Biosciences compare to Finch Therapeutics Group?

Summary

How does Artelo Biosciences compare to Chemomab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artelo Biosciences (ARTL) Competitors

ARTL vs. LIAN, BFRG, LNAI, FNCH, and CMMB

How does Artelo Biosciences compare to LianBio?

Do analysts recommend LIAN or ARTL?

Which has preferable earnings & valuation, LIAN or ARTL?

Does the media favor LIAN or ARTL?

Is LIAN or ARTL more profitable?

Which has more risk & volatility, LIAN or ARTL?

Do institutionals and insiders hold more shares of LIAN or ARTL?

Summary

How does Artelo Biosciences compare to Bullfrog AI?

Do insiders & institutionals hold more shares of ARTL or BFRG?

Which has better earnings and valuation, ARTL or BFRG?

Do analysts prefer ARTL or BFRG?

Which has more volatility and risk, ARTL or BFRG?

Does the media favor ARTL or BFRG?

Is ARTL or BFRG more profitable?

Summary

How does Artelo Biosciences compare to Lunai Bioworks?

Which has better valuation & earnings, LNAI or ARTL?

Do analysts prefer LNAI or ARTL?

Does the media prefer LNAI or ARTL?

Which has more volatility & risk, LNAI or ARTL?

Is LNAI or ARTL more profitable?

Do institutionals & insiders believe in LNAI or ARTL?

Summary

How does Artelo Biosciences compare to Finch Therapeutics Group?

Is ARTL or FNCH more profitable?

Do analysts recommend ARTL or FNCH?

Do institutionals and insiders believe in ARTL or FNCH?

Which has more risk and volatility, ARTL or FNCH?

Which has stronger earnings and valuation, ARTL or FNCH?

Does the media favor ARTL or FNCH?

Summary

How does Artelo Biosciences compare to Chemomab Therapeutics?

Does the media favor ARTL or CMMB?

Do analysts recommend ARTL or CMMB?

Which has more volatility and risk, ARTL or CMMB?

Do institutionals & insiders believe in ARTL or CMMB?

Is ARTL or CMMB more profitable?

Which has better valuation and earnings, ARTL or CMMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools